Neobe selected to pitch at the 2025 Anglonordic Life Sciences Conference
Neobe, a preclinical startup engineering microbial vectors to break down barriers to curative responses in solit rumours, recently attended and presented at the Anglonordic Life Sciences Conference, a leading international event bringing together companies, investors and industry leaders from the European life sciences space.
Our co-founder and CEO Pedro Correa de Sampaio participated in the conference where he presented recent company milestones, including compelling pre-clinical data demonstrating the ability of lead asset NEO22 to enable responses to antibody based therapies in refractory mouse models thorugh localized precision stromal remodeling. The event provided a fantastic opportunity to engage in discussions with potential investors and collaborative partners.
Neobe Therapeutics’ attendance underscores its continued commitment to building strong relationships with industry leaders and investors within the life science ecosystem and advancing its mission to bring curative oncology therapies to solid tumour patients.
